APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study

• Published in: Neurology Vol. 64; no. 9; p. 1531
• Main Authors: Dufouil, C, Richard, F, Fiévet, N, Dartigues, J F, Ritchie, K, Tzourio, C, Amouyel, P, Alpérovitch, A
• Format: Journal Article
• Language: English
• Published: United States 10.05.2005
• Subjects: Aged; Aged, 80 and over; Apolipoprotein E4; Apolipoproteins E - genetics; Causality; Cholesterol - blood; Clofibric Acid - therapeutic use; Cohort Studies; Cross-Sectional Studies; Dementia - blood; Dementia - epidemiology; Dementia - genetics; Female; France - epidemiology; Genetic Predisposition to Disease - genetics; Genetic Testing; Genotype; Health Surveys; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hyperlipidemias - drug therapy; Hyperlipidemias - epidemiology; Hyperlipidemias - genetics; Hypolipidemic Agents - therapeutic use; Male; Prospective Studies; Surveys and Questionnaires; France

To examine the association of plasma cholesterol levels, lipid-lowering agent (LLA) intake, and APOE genotype with dementia prevalence. The Three-City Study is a population-based cohort of 9,294 subjects selected from the electoral rolls of three French cities (Bordeaux, Dijon, Montpellier). Baselin...